Print ISSN: 2394-6369
Online ISSN: 2394-6377
CODEN : IJCBK6
International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...Review Article
Author Details :
Volume : 11, Issue : 4, Year : 2024
Article Page : 223-228
https://doi.org/10.18231/j.ijcbr.2024.033
Abstract
The gut microbiome plays a crucial role in modulating the immune response to cancer immunotherapies, particularly anti-PD-1 inhibitors, which have revolutionized the treatment of melanoma. Despite the success of these therapies in some patients, the response remains highly variable. Recent studies suggest that the composition and diversity of the gut microbiome can influence the efficacy of anti-PD-1 therapy by shaping systemic immunity, particularly through its effects on T-cell activation and tumor microenvironment dynamics. Specific microbial species, such as Akkermansia muciniphila and Bifidobacterium, as well as microbial metabolites like short-chain fatty acids (SCFAs), have been associated with enhanced immune responses and improved treatment outcomes. Conversely, dysbiosis, or microbial imbalance, has been linked to resistance to immunotherapy. This review explores the mechanisms by which the microbiome influences immune responses and discusses strategies such as fecal microbiota transplantation (FMT), dietary interventions, and probiotics to modulate the microbiome and enhance melanoma treatment outcomes. Understanding the microbiome's role in immunotherapy could lead to more personalized, effective treatment strategies for melanoma and other cancers.
Keywords: Melanoma, Immune checkpoint inhibitors, Anti-PD-1 therapy, Pembrolizumab, Nivolumab
How to cite : Nawal H, Exploring the role of the gut microbiome in modulating response to anti-PD-1 immunotherapy in melanoma patients. Int J Clin Biochem Res 2024;11(4):223-228
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.